NYSE:RMDResMed Stock Price, Forecast & News

$153.71

-6.77 (-4.22 %)

(As of 05/27/2020 04:00 PM ET)

Add

Compare

Today's Range

$149.16

Now: $153.71▼

$159.74

50-Day Range

$153.68

MA: $161.19▼

$169.28

52-Week Range

$108.85

Now: $153.71▼

$177.99

Volume1.02 million shs

Average Volume740,046 shs

Market Capitalization$22.24 billion

P/E Ratio43.54

Dividend Yield0.97%

Beta0.5

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; data communications and control products, such as AirView Diagnostics, EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules; U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; and myAir, a patient engagement application that provides sleep data and a daily score based on their previous night's data, as well as offers business management software and services to medical equipment and home health providers. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

3.1 Analyst's Opinion

Consensus Rating
ResMed has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 3 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $179.67, ResMed has a potential upside of 16.9% from its current price of $153.71.
Amount of Analyst Coverage
ResMed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.8 Community Rank

Outperform Votes
ResMed has received 354 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ResMed has received 633 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ResMed has received 64.13% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote “Outperform” if you believe RMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
ResMed is a leading dividend payer. It pays a dividend yield of 0.97%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
ResMed has only been increasing its dividend for 4 years.
Dividend Coverage
The dividend payout ratio of ResMed is 42.86 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, ResMed will have a dividend payout ratio of 35.21 % next year. This indicates that ResMed will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,752,429.00 in company stock.
Percentage Held by Insiders
Only 1.22% of the stock of ResMed is held by insiders.
Percentage Held by Institutions
67.14% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ResMed are expected to grow by 0.45% in the coming year, from $4.41 to $4.43 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ResMed is 43.54, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.79.
Price to Earnings Ratio vs. Sector
The P/E ratio of ResMed is 43.54, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.06.
Price to Earnings Growth Ratio
ResMed has a PEG Ratio of 2.60. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
ResMed has a P/B Ratio of 9.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.96 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNYSE:RMD

Previous Symbol

CUSIP76115210

CIK943819

Webwww.resmed.com

Phone858-836-5000

Debt

Debt-to-Equity Ratio0.65

Current Ratio2.66

Quick Ratio2.01

Price-To-Earnings

Trailing P/E Ratio43.54

Forward P/E Ratio34.85

P/E Growth2.6

Sales & Book Value

Annual Sales$2.61 billion

Price / Sales8.53

Cash Flow$4.49 per share

Price / Cash Flow34.23

Book Value$15.60 per share

Price / Book9.85

Profitability

EPS (Most Recent Fiscal Year)$3.64

Net Income$404.59 million

Net Margins17.73%

Return on Equity29.26%

Return on Assets14.87%

Miscellaneous

Employees7,240

Outstanding Shares144,668,000

Market Cap$22.24 billion

Next Earnings Date7/23/2020 (Estimated)

OptionableOptionable

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

ResMed (NYSE:RMD) Frequently Asked Questions

How has ResMed's stock been impacted by COVID-19 (Coronavirus)?

ResMed's stock was trading at $153.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RMD shares have increased by 0.1% and is now trading at $153.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ResMed?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for ResMed.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for ResMed.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its earnings results on Thursday, April, 30th. The medical equipment provider reported $1.29 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.00 by $0.29. The medical equipment provider earned $769.50 million during the quarter, compared to the consensus estimate of $717.70 million. ResMed had a return on equity of 29.26% and a net margin of 17.73%. The company's quarterly revenue was up 16.2% on a year-over-year basis. During the same period last year, the company posted $0.89 earnings per share. View ResMed's earnings history.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, April 30th. Stockholders of record on Thursday, May 14th will be paid a dividend of $0.39 per share on Thursday, June 18th. This represents a $1.56 dividend on an annualized basis and a yield of 1.01%. The ex-dividend date is Wednesday, May 13th. View ResMed's dividend history.

What price target have analysts set for RMD?

10 brokerages have issued 12-month price objectives for ResMed's stock. Their forecasts range from $165.00 to $200.00. On average, they expect ResMed's share price to reach $179.67 in the next twelve months. This suggests a possible upside of 16.9% from the stock's current price. View analysts' price targets for ResMed.

Has ResMed been receiving favorable news coverage?

News coverage about RMD stock has trended extremely positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ResMed earned a coverage optimism score of 4.8 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutResMed.

Are investors shorting ResMed?

ResMed saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 1,820,000 shares, an increase of 6.4% from the April 15th total of 1,710,000 shares. Based on an average daily volume of 821,800 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.3% of the shares of the company are sold short. View ResMed's Current Options Chain.

Who are some of ResMed's key competitors?

Some companies that are related to ResMed include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), Teleflex (TFX), Hologic (HOLX), Steris (STE), Masimo (MASI) and Insulet (PODD). View all competitors.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Netflix (NFLX), Walt Disney (DIS), QUALCOMM (QCOM), Adobe (ADBE), Visa (V), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and salesforce.com (CRM).

Who are ResMed's key executives?

ResMed's management team includes the following people:

Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)
Mr. Robert A. Douglas, Pres & COO (Age 59)
Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)
Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)
Mr. James Hollingshead, Pres of Sleep Bus. (Age 56)

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.54%), WCM Investment Management LLC (5.65%), State Street Corp (4.60%), Capital World Investors (3.83%), Baillie Gifford & Co. (3.13%) and Geode Capital Management LLC (1.70%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View institutional ownership trends for ResMed.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Capital World Investors, Retirement Systems of Alabama, Canada Pension Plan Investment Board, Voloridge Investment Management LLC, APG Asset Management N.V., and Blair William & Co. IL. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas, and Ronald R Taylor. View insider buying and selling activity for ResMed.

Which institutional investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., WCM Investment Management LLC, BlackRock Inc., State Street Corp, Sumitomo Mitsui Trust Holdings Inc., Zurich Insurance Group Ltd FI, Robeco Institutional Asset Management B.V., and Swiss National Bank. View insider buying and selling activity for ResMed.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $153.71.

How big of a company is ResMed?

ResMed has a market capitalization of $22.24 billion and generates $2.61 billion in revenue each year. The medical equipment provider earns $404.59 million in net income (profit) each year or $3.64 on an earnings per share basis. ResMed employs 7,240 workers across the globe.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]com.

This page was last updated on 5/27/2020 by MarketBeat.com Staff